Your browser doesn't support javascript.
loading
Anatomic position determines oncogenic specificity in melanoma.
Weiss, Joshua M; Hunter, Miranda V; Cruz, Nelly M; Baggiolini, Arianna; Tagore, Mohita; Ma, Yilun; Misale, Sandra; Marasco, Michelangelo; Simon-Vermot, Theresa; Campbell, Nathaniel R; Newell, Felicity; Wilmott, James S; Johansson, Peter A; Thompson, John F; Long, Georgina V; Pearson, John V; Mann, Graham J; Scolyer, Richard A; Waddell, Nicola; Montal, Emily D; Huang, Ting-Hsiang; Jonsson, Philip; Donoghue, Mark T A; Harris, Christopher C; Taylor, Barry S; Xu, Tianhao; Chaligné, Ronan; Shliaha, Pavel V; Hendrickson, Ronald; Jungbluth, Achim A; Lezcano, Cecilia; Koche, Richard; Studer, Lorenz; Ariyan, Charlotte E; Solit, David B; Wolchok, Jedd D; Merghoub, Taha; Rosen, Neal; Hayward, Nicholas K; White, Richard M.
Afiliación
  • Weiss JM; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
  • Hunter MV; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cruz NM; Cell and Developmental Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
  • Baggiolini A; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tagore M; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ma Y; Developmental Biology, The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Misale S; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Marasco M; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
  • Simon-Vermot T; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Campbell NR; Cell and Developmental Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
  • Newell F; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wilmott JS; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Johansson PA; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Thompson JF; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
  • Long GV; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pearson JV; Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mann GJ; Physiology, Biophysics & Systems Biology Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
  • Scolyer RA; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Waddell N; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Montal ED; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Huang TH; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Jonsson P; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Donoghue MTA; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Harris CC; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Taylor BS; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Xu T; Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Chaligné R; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Shliaha PV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Hendrickson R; John Curtin School of Medical Research, Australian National University, Acton, Australian Capital Territory, Australia.
  • Jungbluth AA; Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, Sydney, New South Wales, Australia.
  • Lezcano C; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Koche R; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Studer L; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Ariyan CE; New South Wales Health Pathology, Sydney, New South Wales, Australia.
  • Solit DB; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Wolchok JD; School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Merghoub T; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rosen N; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hayward NK; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • White RM; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature ; 604(7905): 354-361, 2022 04.
Article en En | MEDLINE | ID: mdl-35355015
ABSTRACT
Oncogenic alterations to DNA are not transforming in all cellular contexts1,2. This may be due to pre-existing transcriptional programmes in the cell of origin. Here we define anatomic position as a major determinant of why cells respond to specific oncogenes. Cutaneous melanoma arises throughout the body, whereas the acral subtype arises on the palms of the hands, soles of the feet or under the nails3. We sequenced the DNA of cutaneous and acral melanomas from a large cohort of human patients and found a specific enrichment for BRAF mutations in cutaneous melanoma and enrichment for CRKL amplifications in acral melanoma. We modelled these changes in transgenic zebrafish models and found that CRKL-driven tumours formed predominantly in the fins of the fish. The fins are the evolutionary precursors to tetrapod limbs, indicating that melanocytes in these acral locations may be uniquely susceptible to CRKL. RNA profiling of these fin and limb melanocytes, when compared with body melanocytes, revealed a positional identity gene programme typified by posterior HOX13 genes. This positional gene programme synergized with CRKL to amplify insulin-like growth factor (IGF) signalling and drive tumours at acral sites. Abrogation of this CRKL-driven programme eliminated the anatomic specificity of acral melanoma. These data suggest that the anatomic position of the cell of origin endows it with a unique transcriptional state that makes it susceptible to only certain oncogenic insults.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos